Journal articles on the topic 'Pathological hypertrophy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Pathological hypertrophy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Li, Wei-ming, Yi-fan Zhao, Guo-fu Zhu, Wen-hui Peng, Meng-yun Zhu, Xue-jing Yu, Wei Chen, Da-chun Xu, and Ya-wei Xu. "Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload." Clinical Science 131, no. 2 (December 23, 2016): 141–54. http://dx.doi.org/10.1042/cs20160664.
Full textYu, Qing, Wenxin Kou, Xu Xu, Shunping Zhou, Peipei Luan, Xiaopeng Xu, Hailing Li, et al. "FNDC5/Irisin inhibits pathological cardiac hypertrophy." Clinical Science 133, no. 5 (March 1, 2019): 611–27. http://dx.doi.org/10.1042/cs20190016.
Full textKang, Peter M., Patrick Yue, Zhilin Liu, Oleg Tarnavski, Natalya Bodyak, and Seigo Izumo. "Alterations in apoptosis regulatory factors during hypertrophy and heart failure." American Journal of Physiology-Heart and Circulatory Physiology 287, no. 1 (July 2004): H72—H80. http://dx.doi.org/10.1152/ajpheart.00556.2003.
Full textLi, Peng-Long, Hui Liu, Guo-Peng Chen, Ling Li, Hong-Jie Shi, Hong-Yu Nie, Zhen Liu, et al. "STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) Inhibits Pathological Cardiac Hypertrophy." Hypertension 76, no. 4 (October 2020): 1219–30. http://dx.doi.org/10.1161/hypertensionaha.120.14752.
Full textJACOB, R., M. VOGT, and H. RUPP. "Physiological and pathological hypertrophy*." Journal of Molecular and Cellular Cardiology 18 (1986): 35. http://dx.doi.org/10.1016/s0022-2828(86)80135-3.
Full textTanaka, M., H. Fujiwara, and C. Kawai. "Pathological features of hypertrophic cardiomyopathy without asymmetrical septal hypertrophy." Heart 56, no. 3 (September 1, 1986): 294–97. http://dx.doi.org/10.1136/hrt.56.3.294.
Full textHu, Chengyun, Feibiao Dai, Jiawu Wang, Lai Jiang, Di Wang, Jie Gao, Jun Huang, et al. "Peroxiredoxin-5 Knockdown Accelerates Pressure Overload-Induced Cardiac Hypertrophy in Mice." Oxidative Medicine and Cellular Longevity 2022 (January 29, 2022): 1–12. http://dx.doi.org/10.1155/2022/5067544.
Full textLu, Dan, Jizheng Wang, Jing Li, Feifei Guan, Xu Zhang, Wei Dong, Ning Liu, Shan Gao, and Lianfeng Zhang. "Meox1 accelerates myocardial hypertrophic decompensation through Gata4." Cardiovascular Research 114, no. 2 (November 16, 2017): 300–311. http://dx.doi.org/10.1093/cvr/cvx222.
Full textGao, Si, Xue-ping Liu, Li-hua Wei, Jing Lu, and Peiqing Liu. "Upregulation of α-enolase protects cardiomyocytes from phenylephrine-induced hypertrophy." Canadian Journal of Physiology and Pharmacology 96, no. 4 (April 2018): 352–58. http://dx.doi.org/10.1139/cjpp-2017-0282.
Full textLuckey, Stephen W., Chris D. Haines, John P. Konhilas, Elizabeth D. Luczak, Antke Messmer-Kratzsch, and Leslie A. Leinwand. "Cyclin D2 is a critical mediator of exercise-induced cardiac hypertrophy." Experimental Biology and Medicine 242, no. 18 (September 13, 2017): 1820–30. http://dx.doi.org/10.1177/1535370217731503.
Full textZeitz, Michael J., and James W. Smyth. "Translating Translation to Mechanisms of Cardiac Hypertrophy." Journal of Cardiovascular Development and Disease 7, no. 1 (March 10, 2020): 9. http://dx.doi.org/10.3390/jcdd7010009.
Full textYuan, Yonggang, Wanzhong Peng, Yongxing Liu, and Zesheng Xu. "Palmatine attenuates isoproterenol-induced pathological hypertrophy via selectively inhibiting HDAC2 in rats." International Journal of Immunopathology and Pharmacology 30, no. 4 (November 22, 2017): 406–12. http://dx.doi.org/10.1177/0394632017742225.
Full textJoseph, Jacob, Lija Joseph, Nawal S. Shekhawat, Sulochana Devi, Junru Wang, Russell B. Melchert, Martin Hauer-Jensen, and Richard H. Kennedy. "Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats." American Journal of Physiology-Heart and Circulatory Physiology 285, no. 2 (August 2003): H679—H686. http://dx.doi.org/10.1152/ajpheart.00145.2003.
Full textZhou, Ning, Shaunrick Stoll, and Hongyu Qiu. "VCP represses pathological cardiac hypertrophy." Aging 9, no. 12 (December 26, 2017): 2469–70. http://dx.doi.org/10.18632/aging.101357.
Full textShimizu, Ippei, and Tohru Minamino. "Physiological and pathological cardiac hypertrophy." Journal of Molecular and Cellular Cardiology 97 (August 2016): 245–62. http://dx.doi.org/10.1016/j.yjmcc.2016.06.001.
Full textKavazis, Andreas N. "Pathological vs. physiological cardiac hypertrophy." Journal of Physiology 593, no. 17 (September 1, 2015): 3767. http://dx.doi.org/10.1113/jp271161.
Full textHarrison, Brooke C., Charles R. Roberts, David B. Hood, Meghan Sweeney, Jody M. Gould, Erik W. Bush, and Timothy A. McKinsey. "The CRM1 Nuclear Export Receptor Controls Pathological Cardiac Gene Expression." Molecular and Cellular Biology 24, no. 24 (December 15, 2004): 10636–49. http://dx.doi.org/10.1128/mcb.24.24.10636-10649.2004.
Full textLiao, Hai-han, Nan Zhang, Yan-yan Meng, Hong Feng, Jing-jing Yang, Wen-jin Li, Si Chen, Hai-ming Wu, Wei Deng, and Qi-zhu Tang. "Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway." Oxidative Medicine and Cellular Longevity 2019 (December 6, 2019): 1–14. http://dx.doi.org/10.1155/2019/6304058.
Full textYang, Jin, Xuhui Feng, Qiong Zhou, Wei Cheng, Ching Shang, Pei Han, Chiou-Hong Lin, Huei-Sheng Vincent Chen, Thomas Quertermous, and Ching-Pin Chang. "Pathological Ace2-to-Ace enzyme switch in the stressed heart is transcriptionally controlled by the endothelial Brg1–FoxM1 complex." Proceedings of the National Academy of Sciences 113, no. 38 (September 6, 2016): E5628—E5635. http://dx.doi.org/10.1073/pnas.1525078113.
Full textBrown, R. Dale, S. Kelly Ambler, Min Li, Timothy M. Sullivan, Lauren N. Henry, Joseph T. Crossno, Carlin S. Long, Timothy P. Garrington, and Kurt R. Stenmark. "MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension." American Journal of Physiology-Heart and Circulatory Physiology 304, no. 2 (January 15, 2013): H269—H281. http://dx.doi.org/10.1152/ajpheart.00158.2012.
Full textBuss, Sebastian J., Johannes H. Riffel, Pratima Malekar, Marco Hagenmueller, Christina Asel, Min Zhang, Celine Weiss, Hugo A. Katus, and Stefan E. Hardt. "Chronic Akt blockade aggravates pathological hypertrophy and inhibits physiological hypertrophy." American Journal of Physiology-Heart and Circulatory Physiology 302, no. 2 (January 2012): H420—H430. http://dx.doi.org/10.1152/ajpheart.00211.2011.
Full textDeng, Yawen, Zhitong Li, Xiangbo An, Rui Fan, Yao Wang, Jiatian Li, Xiaolei Yang, Jiawei Liao, and Yunlong Xia. "Hyperhomocysteinemia Promotes Cardiac Hypertrophy in Hypertension." Oxidative Medicine and Cellular Longevity 2022 (August 22, 2022): 1–16. http://dx.doi.org/10.1155/2022/1486157.
Full textKong, Sek Won, Natalya Bodyak, Patrick Yue, Zhilin Liu, Jeffrey Brown, Seigo Izumo, and Peter M. Kang. "Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats." Physiological Genomics 21, no. 1 (March 21, 2005): 34–42. http://dx.doi.org/10.1152/physiolgenomics.00226.2004.
Full textAgo, Tetsuro, and Junichi Sadoshima. "From Contractile Enhancement to Pathological Hypertrophy." Journal of the American College of Cardiology 66, no. 3 (July 2015): 273–77. http://dx.doi.org/10.1016/j.jacc.2015.05.058.
Full textWehbe, Nadine, Suzanne Nasser, Gianfranco Pintus, Adnan Badran, Ali Eid, and Elias Baydoun. "MicroRNAs in Cardiac Hypertrophy." International Journal of Molecular Sciences 20, no. 19 (September 23, 2019): 4714. http://dx.doi.org/10.3390/ijms20194714.
Full textXie, Xin, Hai-Lian Bi, Song Lai, Yun-Long Zhang, Nan Li, Hua-Jun Cao, Ling Han, Hong-Xia Wang, and Hui-Hua Li. "The immunoproteasome catalytic β5i subunit regulates cardiac hypertrophy by targeting the autophagy protein ATG5 for degradation." Science Advances 5, no. 5 (May 2019): eaau0495. http://dx.doi.org/10.1126/sciadv.aau0495.
Full textWatson, Peter A., Jane E. B. Reusch, Sylvia A. McCune, Leslie A. Leinwand, Stephen W. Luckey, John P. Konhilas, David A. Brown, et al. "Restoration of CREB function is linked to completion and stabilization of adaptive cardiac hypertrophy in response to exercise." American Journal of Physiology-Heart and Circulatory Physiology 293, no. 1 (July 2007): H246—H259. http://dx.doi.org/10.1152/ajpheart.00734.2006.
Full textOldfield, Christopher J., Todd A. Duhamel, and Naranjan S. Dhalla. "Mechanisms for the transition from physiological to pathological cardiac hypertrophy." Canadian Journal of Physiology and Pharmacology 98, no. 2 (February 2020): 74–84. http://dx.doi.org/10.1139/cjpp-2019-0566.
Full textŢarcă, Elena, Elena Cojocaru, Alina Costina Luca, Laura Mihaela Trandafir, Solange Tamara Roşu, Valentin Munteanu, Viorel Țarcă, Cristian Constantin Budacu, and Claudia Florida Costea. "Unusual Case of Masseter Muscle Hypertrophy in Adolescence—Case Report and Literature Overview." Diagnostics 12, no. 2 (February 16, 2022): 505. http://dx.doi.org/10.3390/diagnostics12020505.
Full textHaines, Christopher D., Pamela A. Harvey, and Leslie A. Leinwand. "Estrogens Mediate Cardiac Hypertrophy in a Stimulus-Dependent Manner." Endocrinology 153, no. 9 (September 1, 2012): 4480–90. http://dx.doi.org/10.1210/en.2012-1353.
Full textQian, Yanxia, Mingming Zhang, Ningtian Zhou, Xiaohan Xu, Jiahui Zhang, Qiang Ding, and Junhong Wang. "A long noncoding RNA CHAIR protects the heart from pathological stress." Clinical Science 134, no. 13 (July 2020): 1843–57. http://dx.doi.org/10.1042/cs20200149.
Full textChen, Lijuan, Jia Huang, Yanxiao Ji, Xiaojing Zhang, Pixiao Wang, Keqiong Deng, Xi Jiang, Genshan Ma, and Hongliang Li. "Tripartite motif 32 prevents pathological cardiac hypertrophy." Clinical Science 130, no. 10 (April 1, 2016): 813–28. http://dx.doi.org/10.1042/cs20150619.
Full textAbibillaev, Damirbek, and Fuat Kocyigit. "Athletic heart adaptation, pathological hypertrophy and sudden cardiac death." Heart, Vessels and Transplantation 4, Issue 2 (May 27, 2020): 55. http://dx.doi.org/10.24969/hvt.2020.199.
Full textGrund, Andrea, Malgorzata Szaroszyk, Janina K. Döppner, Mona Malek Mohammadi, Badder Kattih, Mortimer Korf-Klingebiel, Anna Gigina, et al. "A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload." Cardiovascular Research 115, no. 1 (June 20, 2018): 71–82. http://dx.doi.org/10.1093/cvr/cvy154.
Full textSu, Dongmei, Sun Jing, Lina Guan, Qian Li, Huiling Zhang, Xiaobo Gao, and Xu Ma. "Role of Nodal–PITX2C signaling pathway in glucose-induced cardiomyocyte hypertrophy." Biochemistry and Cell Biology 92, no. 3 (June 2014): 183–90. http://dx.doi.org/10.1139/bcb-2013-0124.
Full textBi, Hai-Lian, Xiao-Li Zhang, Yun-Long Zhang, Xin Xie, Yun-Long Xia, Jie Du, and Hui-Hua Li. "The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor." Science Advances 6, no. 16 (April 2020): eaax4826. http://dx.doi.org/10.1126/sciadv.aax4826.
Full textIemitsu, Motoyuki, Takashi Miyauchi, Seiji Maeda, Satoshi Sakai, Tsutomu Kobayashi, Nobuharu Fujii, Hitoshi Miyazaki, Mitsuo Matsuda, and Iwao Yamaguchi. "Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 281, no. 6 (December 1, 2001): R2029—R2036. http://dx.doi.org/10.1152/ajpregu.2001.281.6.r2029.
Full textGrieco, Teresa, Vito Gomes, Alfredo Rossi, Carmen Cantisani, Maria Elisabetta Greco, Giovanni Rossi, Alvise Sernicola, and Giovanni Pellacani. "The Pathological Culprit of Neuropathic Skin Pain in Long COVID-19 Patients: A Case Series." Journal of Clinical Medicine 11, no. 15 (July 31, 2022): 4474. http://dx.doi.org/10.3390/jcm11154474.
Full textNosenko, N. M., D. V. Shchehlov, M. Yu Mamonova, and Ya E. Kudelskyi. "Left ventricular hypertrophy: differential diagnosis." Endovascular Neuroradiology 30, no. 4 (March 11, 2020): 49–58. http://dx.doi.org/10.26683/2304-9359-2019-4(30)-49-58.
Full textYalçin, Fatih, Nagehan Kucukler, Oscar Cingolani, Blaid Mbiyangandu, Lars Sorensen, Aurelio Pinherio, M. Roselle Abraham, and Theodore P. Abraham. "Evolution of ventricular hypertrophy and myocardial mechanics in physiological and pathological hypertrophy." Journal of Applied Physiology 126, no. 2 (February 1, 2019): 354–62. http://dx.doi.org/10.1152/japplphysiol.00199.2016.
Full textGesmundo, Iacopo, Michele Miragoli, Pierluigi Carullo, Letizia Trovato, Veronica Larcher, Elisa Di Pasquale, Mara Brancaccio, et al. "Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure." Proceedings of the National Academy of Sciences 114, no. 45 (October 25, 2017): 12033–38. http://dx.doi.org/10.1073/pnas.1712612114.
Full textPeng, Shi, Xiao-feng Lu, Yi-ding Qi, Jing Li, Juan Xu, Tian-you Yuan, Xiao-yu Wu, et al. "LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway." Oxidative Medicine and Cellular Longevity 2020 (September 18, 2020): 1–15. http://dx.doi.org/10.1155/2020/9815039.
Full textGallo, Simona, Annapia Vitacolonna, Alessandro Bonzano, Paolo Comoglio, and Tiziana Crepaldi. "ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy." International Journal of Molecular Sciences 20, no. 9 (May 1, 2019): 2164. http://dx.doi.org/10.3390/ijms20092164.
Full textDobrzyn, Pawel, Aleksandra Pyrkowska, Monika K. Duda, Tomasz Bednarski, Michal Maczewski, Jozef Langfort, and Agnieszka Dobrzyn. "Expression of lipogenic genes is upregulated in the heart with exercise training-induced but not pressure overload-induced left ventricular hypertrophy." American Journal of Physiology-Endocrinology and Metabolism 304, no. 12 (June 15, 2013): E1348—E1358. http://dx.doi.org/10.1152/ajpendo.00603.2012.
Full textLi, Haobo, Lena E. Trager, Xiaojun Liu, Margaret H. Hastings, Chunyang Xiao, Justin Guerra, Samantha To, et al. "lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth." Circulation 145, no. 16 (April 19, 2022): 1218–33. http://dx.doi.org/10.1161/circulationaha.121.056850.
Full textPiven, O. O. "Signalling function of β-catenin is important at early stages of adult heart pathological hypertrophy." Visnik ukrains'kogo tovaristva genetikiv i selekcioneriv 14, no. 1 (June 20, 2016): 44–51. http://dx.doi.org/10.7124/visnyk.utgis.14.1.543.
Full textRen, Zongna, Peng Yu, Dandan Li, Zheng Li, Yingnan Liao, Yin Wang, Bingying Zhou, and Li Wang. "Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy." Circulation 141, no. 21 (May 26, 2020): 1704–19. http://dx.doi.org/10.1161/circulationaha.119.043053.
Full textLiu, Yaoqiu, Yahui Shen, Jingai Zhu, Ming Liu, Xing Li, Yumei Chen, Xiangqing Kong, Guixian Song, and Lingmei Qian. "Cardiac-Specific PID1 Overexpression Enhances Pressure Overload-Induced Cardiac Hypertrophy in Mice." Cellular Physiology and Biochemistry 35, no. 5 (2015): 1975–85. http://dx.doi.org/10.1159/000374005.
Full textLi, Jin, Zhao Sha, Xiaolan Zhu, Wanru Xu, Weilin Yuan, Tingting Yang, Bing Jin, et al. "Targeting miR-30d reverses pathological cardiac hypertrophy." eBioMedicine 81 (July 2022): 104108. http://dx.doi.org/10.1016/j.ebiom.2022.104108.
Full textLi, Zhenhua, Jian Wang, and Xiao Yang. "Functions of Autophagy in Pathological Cardiac Hypertrophy." International Journal of Biological Sciences 11, no. 6 (2015): 672–78. http://dx.doi.org/10.7150/ijbs.11883.
Full text